EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Clinical trials for EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) explained in plain language.
Never miss a new study
Get alerted when new EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) trials appear
Sign up with your email to follow new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug duo targets aggressive lung cancer after standard treatments fail
Disease control Not yet recruitingThis study is testing a new combination of two drugs, sacituzumab tirumotecan and anlotinib, for people with extensive-stage small cell lung cancer that has gotten worse after their first treatment. The goal is to see if this two-drug approach can shrink tumors and control the ca…
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Sichuan University • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New weapon in fight against aggressive lung cancer
Disease control Not yet recruitingThis study is testing whether adding a new medicine called obrixtamig to standard treatment helps people with advanced small cell lung cancer live longer. About 670 adults who haven't had treatment for this advanced stage will be randomly assigned to receive either the standard t…
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC